Edition:
United Kingdom

Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

5.21USD
18 May 2018
Change (% chg)

$-0.03 (-0.57%)
Prev Close
$5.24
Open
$5.29
Day's High
$5.29
Day's Low
$5.20
Volume
3,462
Avg. Vol
9,735
52-wk High
$15.34
52-wk Low
$5.01

Summary

Name Age Since Current Position

Jeffrey Bailey

55 2018 Chairman of the Board

John Longenecker

70 2018 Interim President, Chief Executive Officer

Evan Lippman

2015 Chief Financial Officer and Business Officer, Senior Vice President

Manuel Aivado

2014 Senior Vice President and Chief Medical Officer

D. Allen Annis

2007 Vice President - Biophysical and Analytical Technologies

Seth Harrison

56 2016 Director

Biographies

Name Description

Jeffrey Bailey

Mr. Jeffrey A. Bailey is Chairman of the Board of the Company. Mr. Bailey currently serves as interim Chief Executive Officer and director of IlluminOss, Inc., a medical device company developing and marketing orthopedic fracture repair products, a position he has held since January 2018. Previously, he served as Executive Chairman of Neurovance, Inc., a private clinical-stage pharmaceutical company, beginning in December 2015, and Chief Executive Officer of Neurovance, Inc. beginning in November 2016, until its acquisition by Otsuka Pharmaceutical Co., Ltd., which was announced in March 2017. From January 2013 through June 2015, Mr. Bailey also served as President and Chief Executive Officer and director of Lantheus Medical Imaging, Inc., a public company providing diagnostic imaging agents. Prior to 2013, Mr. Bailey held various leadership positions with several public and private pharmaceutical and medical device companies, including operating unit President at Novartis Pharmaceuticals and a 22-year career with Johnson & Johnson (including Janssen Pharmaceutica NV).

John Longenecker

Dr. John P. Longenecker is Interim President, Chief Executive Officer of the company. He has provided independent consulting services to biopharmaceutical companies since April 2008. He also served as president and chief executive officer and as a director of HemaQuest Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of therapeutics for blood diseases, from September 2010 until March 2014. From February 2002 to January 2009, Dr. Longenecker was president and chief executive officer and a member of the board of directors of Favrille, Inc., a publicly traded biopharmaceutical company. He has served as a director of Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, since July 2007. Dr. Longenecker holds a B.S. in chemistry/education from Purdue University and a Ph.D. in biochemistry from The Australian National University. He was a post-doctoral fellow at Stanford University from 1980 to 1982.

Evan Lippman

Mr. Evan Lippman is Chief Financial Officer and Business Officer, Senior Vice President of the Company. He began his career in corporate finance and investment banking, managing equity, debt and M&A processes, working with such companies as Bank of America, and Bear Stearns. Prior to joining Aileron, Mr. Lippman was Senior Vice President at EMD Serono, Inc., leading the strategic direction of the US Neurology franchise, as well as managing its operations related to sales, marketing and support services. Mr. Lippman joined EMD Serono from AstraZeneca, where he served as Executive Director of the company’s multi-billion dollar brands, Crestor® and Nexium®, as well as the general Primary Care Portfolio. While at AstraZeneca, Mr. Lippman also held other roles including Head of US Business Development. Prior to AstraZeneca, he worked at Pfizer as Executive Director, Worldwide Business Development and Strategic Planning. Mr. Lippman holds a Bachelor of Arts in Political Science from Bucknell University, a Bachelor of Arts in Business from Georgia State University, and a Masters in Business Administration from Cornell University.

Manuel Aivado

Mr. Manuel C. Aivado is Senior Vice President and Chief Medical Officer of the Company. Prior to joining Aileron, Dr. Aivado served as Taiho Oncology’s Vice President of Clinical Development and Pharmacovigilance. In that capacity, he built global clinical development capabilities, and led multiple drug programs ranging from phase 1 through phase 3, most prominently the global development of Teysuno® (S-1), TAS-102 and TAS-120. Prior to Taiho, Dr. Aivado held positions of increasing responsibility at GlaxoSmithKline, including as Senior Medical Director in the Clinical Development group, where he was involved in numerous drug programs including ofatumumab (Arzerra®), trametinib (Mekinist®), pazopanib (Votrient®), and eltrombopag (Promacta®). Prior to his industry experience, Dr. Aivado practiced ten years of clinical medicine in Germany. During his clinical career, he directed various molecular cancer research projects, which led him to be awarded the prestigious Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado was previously an Instructor in Medicine at Beth Israel Deaconess Medical Center/Harvard Medical School, where he led the first ever-conducted proteomics research project in Myelodysplastic Syndromes (MDS). During his work in academia and in the pharmaceutical industry, Dr. Aivado’s work has culminated in more than 50 peer-reviewed papers, including research articles in Lancet, Nature Genetics and PNAS. Dr. Aivado is a member of the American Society of Hematology and a member of the American Society of Clinical Oncology. Dr. Aivado is a German Board-certified physician for Internal Medicine, Hematology, and Medical Oncology, and he earned an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany.

D. Allen Annis

Dr. D. Allen Annis, Ph.D. is the Vice President - Biophysical and Analytical Technologies of Aileron Therapeutics, Inc. He has served as our Senior Director of Biophysical and Analytical Technologies since November of 2007. He was previously Director of Technology Development at the Schering-Plough Research Institute in Cambridge, MA, and prior to that he was Vice President of New Technologies at NeoGenesis Pharmaceuticals, which was acquired by Schering in 2005. While at NeoGenesis, Dr. Annis co-developed its core drug discovery platform, the affinity selection-mass spectrometry-based Automated Ligand Identification System (ALIS). Dr. Annis authored several patents and publications that describe the ALIS technology, and invented many novel techniques that use ALIS to study protein-drug interactions. Dr. Annis received his B.S. in chemistry from the Georgia Institute of Technology and received his Ph.D. in chemistry from Harvard University.

Seth Harrison

Dr. Seth L. Harrison, M.D. is the Director of Aileron Therapeutics, Inc. He is the Founder and Managing General Partner of Apple Tree Partners. He serves on the Board of Directors of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides. Dr. Harrison received a Bachelor of Arts from Princeton University, a Doctor of Medicine and Master of Business Administration from Columbia University and completed a surgery internship at the New York Presbyterian Hospital.

Basic Compensation

Options Compensation